MedTrace Logo

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

NCT03878888 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-12-17

No results posted yet for this study

Summary

To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay

Conditions

  • Postoperative Pain
  • Surgery
  • Anesthesia, Local

Interventions

DRUG

Exparel 266 MG Per 20 ML Injection

patients receive Exparel in bilateral TAP blocks for open abdomen surgery

Sponsors & Collaborators

  • St. Luke's Hospital, Pennsylvania

    lead OTHER

Principal Investigators

  • Anna Ng Pellegrino, MD · St. Luke's University Health Network - Anesthesia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2019-07-01
Completion
2019-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03878888 on ClinicalTrials.gov